Astellas Data from SKYLIGHT 1™ and SKYLIGHT 2™ Phase 3 Trials of Fezolinetant for the Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause

Genevieve Neal-Perry, M.D., Ph.D., Chair, UNC School of Medicine Department of Obstetrics and Gynecology, discusses the data from the Phase 3 SKYLIGHT 1™ 12-week clinical trial and Phase 3 SKYLIGHT 2™ 52-week clinical trial investigating the efficacy and safety of fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor symptoms associated with menopause (VMS). VMS, characterized by hot flashes (also called hot flushes) and/or night sweats, are common symptoms of menopause. The Phase 3 SKYLIGHT 1™ 12-week clinical data was presented at the American College of Obstetricians and Gynecologists (ACOG) 2022 Annual Meeting and the Phase 3 SKYLIGHT 2™ 52-week data was presented at the Endocrine Society (ENDO) 2022 Annual Meeting.

Dr. Genevieve Neal-Perry, MD, PhD was born and raised in New Jersey. She earned her bachelor’s degree from Dartmouth College and obtained her MD/PhD in pharmacology from Robert WoodJohnson Medical School and The University of Medicine and Dentistry of New Jersey. Dr. Neal-Perry completed residency and fellowship training in reproductive endocrinology and infertility (REI) at Beth Israel Medical Center and Montefiore Medical Center, respectively. Upon completion of fellowship, she joined faculty at the Albert Einstein College of Medicine where she rose to the rank of Associate Professor in Obstetrics and Gynecology and Neuroscience. While at Einstein College of Medicine she served as the REI division researchand fellowship director as well as the Associate Dean for Diversity and Mentoring.In 2015, Dr. Neal-Perry joined the Department of OB/GYN at the University of Washington where she was recruited to be the Director of the Division of Reproductive Endocrinology andInfertility. While at the University of Washington, she lead the creation and opening of the Cancer and Reproduction Clinic at the Seattle Cancer Care Alliance and she was instrumental in developing the inaugural employee discount program for fertility service the University of Washington faculty, students and employees.In April 2020, Dr. Neal-Perry was appointed as Chair with tenure for the UNC Department of Obstetrics and Gynecology here in Chapel Hill. Dr. Neal-Perry research program has focused on the menopause and the impact of nutrition on reproductive andfertility outcomes. She has published a wide range of original research manuscripts, reviews, and book chapters inthe field of reproductive science. Additionally, Dr. Neal-Perry is a national leadership in women’s health researchand reproductive endocrinology. Her leadership roles have included serving as a NIH study section member for Integrative and Clinical Endocrinology and Reproduction Study Section and the Chair and a member of the Reproductive, Andrology and Gynecology study section. She has also served as a member of the REI Division of the American Board of Obstetrics and Gynecology, and Basic Science Vice President for the Endocrine Society. She is an Associate Editor for the Journal of Clinical Endocrinology and Metabolism and a scientific advisor for Endocrinology.Dr. Neal-Perry’s clinical interest and expertise include general infertility, cancer and reproductive health, PCOS, invitro fertilization, third party reproduction, single and same sex reproduction, nutrition and fertility, prematureovarian insufficiency, ovarian aging, menopause and perimenopause complaints, and menstrual cycle dysfunction.She specializes in minimally invasive surgical procedures intended to restore fertility including ovarian cyst removal,tubal reconstruction and uterine polyp and fibroid management.